F/M Emerald Life Sciences Innovation ETF

LFSC
ETF Ticker

+16.37%

+40.04%

NASDAQ

Equity

United States

Thematic

The F/M Emerald Life Sciences Innovation ETF, LFSC_US, is an actively managed strategy providing exposure to United States, Thematic Equity. It is listed on the NASDAQ and has assets under management of $127.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Oct 31, 2024. It has a net expense ratio of 54bps. (All data in USD as of Oct 9, 2026 unless stated.)

The investment philosophy driving the actively managed F/m Emerald Life Sciences Innovation ETF applies a proprietary 10-step research process to identify U.S.-focused life sciences innovators across biotechnology, pharmaceuticals, medical devices, diagnostics, health care services, health-tech and synthetic biology, with capacity and liquidity vetted at the security and subsector level. Under normal conditions, ≥80% of net assets are invested in equity securities of life sciences companies demonstrating technological advancement, market disruption or effective use of AI; up to 20% may be in non-U.S. issuers (including ADRs), all in USD terms. Eligible instruments include common and preferred stock, depositary receipts, IPOs and qualified private placements. Portfolio construction is bottom-up with diversification across life-sciences subsectors; issuer weights reflect conviction, liquidity and risk controls rather than benchmark ties. Rebalancing and sells are driven by deterioration in innovation criteria, valuation/risk limits, liquidity changes or superior opportunities, with ongoing monitoring of regulatory and pipeline catalysts.

ETF Details

Key Facts

Issuer:
F/m Investments
AUM:
$127.0m (as of Aug 31, 2026)
Net Expense Ratio:
54 bps
Inception Date:
Oct 31, 2024
Index:
Actively managed strategy
Dividend Frequency:
N/A

Trading

Ticker:
LFSC
Exchange:
NASDAQ
ISIN:
US74933W2219
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
United States
Theme:
Thematic
Economic Development:
Developed Markets
1 Year Volatility:
27.64%
3 Year Volatility:
N/A
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
0.00% (verify with issuer)
1 Month Performance:
-6.91%
3 Month Performance:
-10.06%
6 Month Performance:
18.65%
1 Year Performance:
40.04%
3 Year Performance:
N/A
5 Year Performance:
N/A
Investment Proposition

F/M Emerald Life Sciences Innovation ETF (LFSC) presents actively managed exposure to U.S. and global life sciences innovators across therapeutics, diagnostics, tools, and enabling technologies. The strategy seeks long-term capital appreciation by concentrating on companies pursuing defensible intellectual property, scalable platforms, or differentiated clinical pipelines, while dynamically adjusting position sizes as milestones, funding conditions, and regulatory catalysts evolve. Portfolio construction emphasizes research-driven security selection, with diversification across development stages to balance binary clinical risks against commercial durability. Return potential is tied to discovery productivity, partnership activity, and market adoption; risks are elevated given scientific, regulatory, and financing uncertainty, along with style cyclicality versus broader healthcare. The fund can operate as a thematic satellite for growth-oriented allocations, a healthcare innovation sleeve to complement diversified sector exposure, or a tactical vehicle for accessing catalyst-rich pipelines. It suits investors following barbell growth strategies or thematic mandates seeking idiosyncratic alpha sources. The fund may excel when capital markets are supportive of R&D and risk appetite improves, and can be challenged during risk-off regimes or reimbursement overhangs. Key risk to monitor: portfolio concentration in clinical-stage names can magnify drawdowns around trial outcomes.

ETF Analytics

Fund Discovery

4 Suggestions